Gilead Accelerates Access to HIV Prevention Drug in South Africa
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Accelerated Drug Access: Gilead collaborates with the South African government and the Global Fund to expedite access to lenacapavir, aiming to provide faster drug supply to communities affected by HIV, marking a significant advancement in the fight against HIV.
- Severe HIV Burden: South Africa bears the highest HIV burden globally, with approximately 7.8 million people living with HIV and an estimated 170,000 new infections annually, disproportionately affecting women, highlighting the urgent need for more effective prevention measures.
- Clinical Trial Commitment: Gilead's Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted in South Africa reflect its commitment to developing solutions in communities most affected by HIV, promoting the drug's efficacy and accessibility.
- Global Supply Strategy: Through royalty-free voluntary licensing agreements with six manufacturers, Gilead supports the provision of lenacapavir across 120 low- and lower-middle-income countries, ensuring long-term, low-cost medication supply to bolster global HIV prevention efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 128.990
Low
105.00
Averages
137.88
High
154.00
Current: 128.990
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The Company also owns an antibody-drug conjugates (ADCs) platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Accelerates Access to HIV Prevention Drug in South Africa
- Accelerated Drug Access: Gilead collaborates with the South African government and the Global Fund to expedite access to lenacapavir, aiming to provide faster drug supply to communities affected by HIV, marking a significant advancement in the fight against HIV.
- Severe HIV Burden: South Africa bears the highest HIV burden globally, with approximately 7.8 million people living with HIV and an estimated 170,000 new infections annually, disproportionately affecting women, highlighting the urgent need for more effective prevention measures.
- Clinical Trial Commitment: Gilead's Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted in South Africa reflect its commitment to developing solutions in communities most affected by HIV, promoting the drug's efficacy and accessibility.
- Global Supply Strategy: Through royalty-free voluntary licensing agreements with six manufacturers, Gilead supports the provision of lenacapavir across 120 low- and lower-middle-income countries, ensuring long-term, low-cost medication supply to bolster global HIV prevention efforts.
See More
Gilead and Lakefront Acquire Ouro Medicines for T Cell Engager Therapies
- Acquisition Completed: Gilead Sciences (GILD) and Lakefront Biotherapeutics (LKFT) have finalized their acquisition of Ouro Medicines for $1.675 billion upfront, plus up to $500 million in potential milestone payments, significantly enhancing their foothold in T cell engager therapies for autoimmune diseases.
- Core Product: The acquisition centers around Gamgertamig (OM336), a phase 1 BCMAxCD3 T cell engager currently under investigation for conditions such as immune thrombocytopenia, Sjögren’s disease, and bullous pemphigoid, indicating strong market potential.
- Market Outlook: This acquisition positions Gilead and Lakefront to better penetrate the rapidly growing autoimmune disease treatment market, which is expected to drive future revenue growth and enhance their competitiveness in the biopharmaceutical sector.
- Strategic Implications: The deal not only strengthens both companies' R&D capabilities in T cell engager therapies but also potentially provides new momentum for their expansion in global markets, aligning with the urgent demand for innovative therapies in the biopharmaceutical industry.
See More
Pharmaceutical Giants Accelerate Acquisitions to Offset Patent Cliffs
- Accelerated Acquisition Activity: In 2026, global biopharma M&A deal value reached $106 billion across 201 transactions, reflecting a strong acquisition appetite among pharmaceutical companies facing patent expirations, with projections suggesting total deal value could exceed $250 billion for the year, marking the sector's best performance since the pre-pandemic peak in 2019.
- Increasing Deal Sizes: The average deal size has climbed to $527.3 million in 2026, up from $365 million in 2025, indicating that pharmaceutical firms are focusing on acquiring high-value assets to enhance their product portfolios and competitive positioning in the market.
- Strategic Acquisition Preferences: Companies are shifting towards strategic “bolt-on” acquisitions in the $1 billion to $5 billion range rather than large leveraged buyouts or mega-mergers, enabling them to quickly supplement near-commercial products while also investing in early-stage assets to access innovative technologies.
- Major Deal Examples: The five largest M&A transactions in 2026 include Sun Pharmaceutical's $11.75 billion acquisition of Organon, Gilead's $7.8 billion purchase of Arcellx, Merck's $6.7 billion acquisition of Terns, Eli Lilly's $7.8 billion deal for Centessa, and Biogen's $5.6 billion acquisition of Apellis, highlighting the industry's consolidation trend and demand for new technologies.
See More
Gilead and Lakefront Complete Acquisition of Ouro Medicines to Expand Inflammation Pipeline
- Acquisition Completed: Gilead has successfully acquired Ouro Medicines for $1.675 billion to advance the development of the T cell engager gamgertamig for autoimmune diseases, enhancing its inflammation portfolio and expanding its clinical development pipeline.
- Clinical Stage Progress: Gamgertamig, a BCMAxCD3 T cell engager, has received Fast Track and Orphan Drug Designation from the FDA, with expectations to enter registrational studies as early as 2027, indicating its potential in treating autoimmune hemolytic anemia and immune thrombocytopenia.
- Collaborative Development Model: Lakefront will oversee the Phase 1/2 clinical studies of gamgertamig, while Gilead will lead the registrational and later-stage studies, ensuring resource and expertise sharing between the two companies to enhance R&D efficiency.
- Financial Arrangements and Future Outlook: The transaction allows Lakefront to acquire Ouro Medicines' team and assets, enabling it to deploy at least $500 million of cash independently for strategic investments, with an expected cash balance of approximately €2 billion by the end of 2026, strengthening its competitive position in the biotechnology sector.
See More
Analysis of XLV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XLV ETF has a 52-week low of $127.96 and a high of $160.59, with the last trade at $152.25, indicating stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and timing for investments.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to stay informed about market dynamics and potential investment opportunities.
See More
Gilead Sciences Reports Positive Phase 3 IDEAL Trial Results for Livdelzi
- Phase 3 Trial Results: Gilead Sciences reported that a significantly higher proportion of patients with primary biliary cholangitis achieved normalization of ALP levels with Livdelzi compared to the placebo group in the Phase 3 IDEAL trial, indicating the drug's potential in improving patient outcomes.
- Patient Recruitment: The trial enrolled 96 adults aged 18 to 75 years, all with ALP levels above the normal range who had not achieved normalization despite treatment with ursodeoxycholic acid (UDCA), highlighting Livdelzi's effectiveness in difficult-to-treat cases.
- Future Plans: Gilead plans to present the full IDEAL trial data at an upcoming medical congress and discuss the results with global regulatory authorities, demonstrating the company's confidence in Livdelzi's market potential.
- Market Performance: Gilead's stock has fluctuated between $104.46 and $157.29 over the past year, closing at $127.57 in the latest trading session, reflecting market interest and anticipation regarding its research advancements.
See More
Gilead Accelerates Access to HIV Prevention Drug in South Africa
- Accelerated Drug Access: Gilead collaborates with the South African government and the Global Fund to expedite access to lenacapavir, aiming to provide faster drug supply to communities affected by HIV, marking a significant advancement in the fight against HIV.
- Severe HIV Burden: South Africa bears the highest HIV burden globally, with approximately 7.8 million people living with HIV and an estimated 170,000 new infections annually, disproportionately affecting women, highlighting the urgent need for more effective prevention measures.
- Clinical Trial Commitment: Gilead's Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted in South Africa reflect its commitment to developing solutions in communities most affected by HIV, promoting the drug's efficacy and accessibility.
- Global Supply Strategy: Through royalty-free voluntary licensing agreements with six manufacturers, Gilead supports the provision of lenacapavir across 120 low- and lower-middle-income countries, ensuring long-term, low-cost medication supply to bolster global HIV prevention efforts.
See More
Gilead and Lakefront Acquire Ouro Medicines for T Cell Engager Therapies
- Acquisition Completed: Gilead Sciences (GILD) and Lakefront Biotherapeutics (LKFT) have finalized their acquisition of Ouro Medicines for $1.675 billion upfront, plus up to $500 million in potential milestone payments, significantly enhancing their foothold in T cell engager therapies for autoimmune diseases.
- Core Product: The acquisition centers around Gamgertamig (OM336), a phase 1 BCMAxCD3 T cell engager currently under investigation for conditions such as immune thrombocytopenia, Sjögren’s disease, and bullous pemphigoid, indicating strong market potential.
- Market Outlook: This acquisition positions Gilead and Lakefront to better penetrate the rapidly growing autoimmune disease treatment market, which is expected to drive future revenue growth and enhance their competitiveness in the biopharmaceutical sector.
- Strategic Implications: The deal not only strengthens both companies' R&D capabilities in T cell engager therapies but also potentially provides new momentum for their expansion in global markets, aligning with the urgent demand for innovative therapies in the biopharmaceutical industry.
See More
Pharmaceutical Giants Accelerate Acquisitions to Offset Patent Cliffs
- Accelerated Acquisition Activity: In 2026, global biopharma M&A deal value reached $106 billion across 201 transactions, reflecting a strong acquisition appetite among pharmaceutical companies facing patent expirations, with projections suggesting total deal value could exceed $250 billion for the year, marking the sector's best performance since the pre-pandemic peak in 2019.
- Increasing Deal Sizes: The average deal size has climbed to $527.3 million in 2026, up from $365 million in 2025, indicating that pharmaceutical firms are focusing on acquiring high-value assets to enhance their product portfolios and competitive positioning in the market.
- Strategic Acquisition Preferences: Companies are shifting towards strategic “bolt-on” acquisitions in the $1 billion to $5 billion range rather than large leveraged buyouts or mega-mergers, enabling them to quickly supplement near-commercial products while also investing in early-stage assets to access innovative technologies.
- Major Deal Examples: The five largest M&A transactions in 2026 include Sun Pharmaceutical's $11.75 billion acquisition of Organon, Gilead's $7.8 billion purchase of Arcellx, Merck's $6.7 billion acquisition of Terns, Eli Lilly's $7.8 billion deal for Centessa, and Biogen's $5.6 billion acquisition of Apellis, highlighting the industry's consolidation trend and demand for new technologies.
See More
Gilead and Lakefront Complete Acquisition of Ouro Medicines to Expand Inflammation Pipeline
- Acquisition Completed: Gilead has successfully acquired Ouro Medicines for $1.675 billion to advance the development of the T cell engager gamgertamig for autoimmune diseases, enhancing its inflammation portfolio and expanding its clinical development pipeline.
- Clinical Stage Progress: Gamgertamig, a BCMAxCD3 T cell engager, has received Fast Track and Orphan Drug Designation from the FDA, with expectations to enter registrational studies as early as 2027, indicating its potential in treating autoimmune hemolytic anemia and immune thrombocytopenia.
- Collaborative Development Model: Lakefront will oversee the Phase 1/2 clinical studies of gamgertamig, while Gilead will lead the registrational and later-stage studies, ensuring resource and expertise sharing between the two companies to enhance R&D efficiency.
- Financial Arrangements and Future Outlook: The transaction allows Lakefront to acquire Ouro Medicines' team and assets, enabling it to deploy at least $500 million of cash independently for strategic investments, with an expected cash balance of approximately €2 billion by the end of 2026, strengthening its competitive position in the biotechnology sector.
See More
Analysis of XLV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XLV ETF has a 52-week low of $127.96 and a high of $160.59, with the last trade at $152.25, indicating stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and timing for investments.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to stay informed about market dynamics and potential investment opportunities.
See More
Gilead Sciences Reports Positive Phase 3 IDEAL Trial Results for Livdelzi
- Phase 3 Trial Results: Gilead Sciences reported that a significantly higher proportion of patients with primary biliary cholangitis achieved normalization of ALP levels with Livdelzi compared to the placebo group in the Phase 3 IDEAL trial, indicating the drug's potential in improving patient outcomes.
- Patient Recruitment: The trial enrolled 96 adults aged 18 to 75 years, all with ALP levels above the normal range who had not achieved normalization despite treatment with ursodeoxycholic acid (UDCA), highlighting Livdelzi's effectiveness in difficult-to-treat cases.
- Future Plans: Gilead plans to present the full IDEAL trial data at an upcoming medical congress and discuss the results with global regulatory authorities, demonstrating the company's confidence in Livdelzi's market potential.
- Market Performance: Gilead's stock has fluctuated between $104.46 and $157.29 over the past year, closing at $127.57 in the latest trading session, reflecting market interest and anticipation regarding its research advancements.
See More
